Literature DB >> 11509603

The recognition of HLA-B27 by human CD4(+) T lymphocytes.

L H Boyle1, J C Goodall, S S Opat, J S Gaston.   

Abstract

HLA-B27 transgenic animal models suggest a role for CD4(+) T lymphocytes in the pathogenesis of the spondyloarthropathies, and murine studies have raised the possibility that unusual forms of B27 may be involved in disease. We demonstrate that CD4(+) T cells capable of recognizing B27 can be isolated from humans by coculture with the MHC class II-negative cell line T2 transfected with B27. These CD4(+) T cells recognize a panel of B27-transfected cell lines that are defective in Ag-processing pathways, but not the nontransfected parental cell lines, in a CD4-dependent fashion. Inhibition of responses by the MHC class I-specific mAb w6/32 and the B27 binding mAb ME1 implicates the recognition of a form of B27 recognized by both of these Abs. We suggest that B27-reactive CD4(+) T cells may be pathogenic in spondyloarthropathies, particularly if factors such as infection influence expression of abnormal forms of B27.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11509603     DOI: 10.4049/jimmunol.167.5.2619

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  Endoplasmic reticulum aminopeptidase-1 alleles associated with increased risk of ankylosing spondylitis reduce HLA-B27 mediated presentation of multiple antigens.

Authors:  Sergey S Seregin; David P W Rastall; Irini Evnouchidou; Charles F Aylsworth; Dionisia Quiroga; Ram P Kamal; Sarah Godbehere-Roosa; Christopher F Blum; Ian A York; Efstratios Stratikos; Andrea Amalfitano
Journal:  Autoimmunity       Date:  2013-09-13       Impact factor: 2.815

2.  Preferential type 1 chemokine receptors and cytokine production of CD28- T cells in ankylosing spondylitis.

Authors:  C Duftner; C Dejaco; W Kullich; A Klauser; C Goldberger; A Falkenbach; M Schirmer
Journal:  Ann Rheum Dis       Date:  2005-10-11       Impact factor: 19.103

3.  High-affinity human leucocyte antigen class I binding variola-derived peptides induce CD4+ T cell responses more than 30 years post-vaccinia virus vaccination.

Authors:  M Wang; S T Tang; O Lund; M H Dziegiel; S Buus; M H Claesson
Journal:  Clin Exp Immunol       Date:  2009-03       Impact factor: 4.330

4.  Gut microbiota amplifies host-intrinsic conversion from the CD8 T cell lineage to CD4 T cells for induction of mucosal immune tolerance.

Authors:  Jen Bon Lui; Lander S McGinn; Zhibin Chen
Journal:  Gut Microbes       Date:  2016

5.  T-cell responses to versican in ankylosing spondylitis.

Authors:  Tae-Jong Kim; Tae-Hwan Kim; Hyun-Joo Lee; Bitnara Lee; A Robin Poole; Robert D Inman
Journal:  Rheumatol Int       Date:  2009-12-11       Impact factor: 2.631

6.  Usage of Conventional PCR Technology for the Detection of HLA-B27 Allele: A Significant Molecular Marker of Ankylosing Spondylitis.

Authors:  Narotam Sharma; Veena Sharma; Tariq Masood; Satish Chandra Nautiyal; Shivani Sailwal; Rajesh K Singh; Rajeev K Kushwaha; R K Singh
Journal:  Indian J Clin Biochem       Date:  2012-09-26

7.  Aberrant expression of microRNAs in T cells from patients with ankylosing spondylitis contributes to the immunopathogenesis.

Authors:  N-S Lai; H-C Yu; H-C Chen; C-L Yu; H-B Huang; M-C Lu
Journal:  Clin Exp Immunol       Date:  2013-07       Impact factor: 4.330

8.  Major histocompatibility complex class I-restricted alloreactive CD4+ T cells.

Authors:  Louise H Boyle; Jane C Goodall; J S Hill Gaston
Journal:  Immunology       Date:  2004-05       Impact factor: 7.397

9.  Intracellular and surface RANKL are differentially regulated in patients with ankylosing spondylitis.

Authors:  Daniela Stupphann; Martina Rauner; Dagmar Krenbek; Janina Patsch; Thomas Pirker; Christian Muschitz; Heinrich Resch; Peter Pietschmann
Journal:  Rheumatol Int       Date:  2008-03-28       Impact factor: 2.631

Review 10.  Disease mechanisms in reactive arthritis.

Authors:  Joachim Sieper
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.